What drives medtech valuations?

Regulatory position and recurring revenue. Buyers assess CE markings, clinical evidence and established reimbursement, together with recurring revenue from consumables, service contracts and device-attached software, when comparing valuations with one-off device sales.

How does the EU Medical Device Regulation affect a sale?

It frames diligence. Buyers verify certification status and expiry under the MDR, the quality-management system, post-market surveillance and any field actions. The regulatory file should document certification status, quality management, surveillance and field actions for buyer review.

Who buys medtech companies from Luxembourg?

International medtech strategics filling portfolio or geographic gaps, and healthcare-focused investors. The buyer pool is global, and processes are run accordingly, in English, against regulatory and clinical diligence standards.

How is our distributor network assessed?

Contract by contract: exclusivity, termination and change-of-control terms, performance history and inventory in the channel. Direct revenue is generally valued above distributor revenue, but well-documented distributor networks with performance data hold value.

Does investment screening apply?

Potentially. The 2023 screening law lists health-related activities as a critical sector, so where a non-EU/EEA acquirer would take control of a Luxembourg medtech business, filing requirements are checked at the outset. EU and EEA buyers are generally outside the regime, but the test looks through to the ultimate controlling investor, so counsel should confirm scope for each buyer.

What support exists for Luxembourg medtech companies?

The national innovation agency Luxinnovation supports qualifying innovation activity, and the SNCI provides medium and long-term financing to Luxembourg companies, directly or through commercial banks. Buyers assess regulatory and commercial evidence in a sale, including records of these operating-stage supports.

Healthcare

What Is a Medical Technology Business Worth? – Luxembourg

A medical technology business typically sells for 8.2x to 15.5x EBITDA. Where yours lands depends on size, growth and owner dependence. Get your instant estimate in EUR below.

Medical Technology Valuation Multiples

EBITDA Multiple11.83x typical

8.19x11.83x15.47x

Revenue Multiple3.64x typical

2.28x3.64x5.46x

Based on middle-market transaction data. Actual multiples vary based on company-specific factors.

Key Value Drivers for Medical Technology

01CE marking and regulatory approval status
02Intellectual property portfolio
03Revenue growth and market penetration
04Clinical evidence and outcomes data
05Reimbursement coverage and coding

Calculate Your Medical Technology Enterprise Value

Complete the form below to get your personalized enterprise value estimate in EUR

How to value a Medical Technology business in Luxembourg

Medical technology companies in Luxembourg are typically specialised developers and manufacturers selling into European and global markets, since the domestic market alone is too small to sustain a medtech business, with the EU regulatory framework as the defining operating condition. Support structures for innovation, including the national agency Luxinnovation and financing through the SNCI, form part of the local backdrop for qualifying companies.

Buyers value medtech businesses on the regulatory and commercial position of the product portfolio: CE markings under the EU Medical Device Regulation, the strength of clinical evidence, reimbursement pathways in target markets, and the installed base with its recurring consumables or service revenue.

Regulatory diligence is the sector's core: certification status and expiry, quality-management systems, post-market surveillance records and any field actions. Commercial diligence follows the distribution model, direct sales versus distributors, and the contractual terms behind each market.

Acquirers are international by nature: medtech strategics filling portfolio gaps and healthcare-focused investors. Health-related activities appear among the critical sectors in Luxembourg's 2023 investment screening law, a point to confirm where non-EU/EEA buyers are involved. Buyers assess recurring revenue from consumables, service and device-attached software when considering premium multiples.